Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Androgen and gonadotropin treatment in females

a technology of androgen and gonadotropin, applied in the field of reproductive technology, can solve the problems of reduced egg production, poor quality eggs produced, and female ovarian function decline, so as to improve the oocyte count of females, improve fertility and reproductive outcomes, and increase oocyte production

Inactive Publication Date: 2014-08-21
GLEICHER NORBERT +2
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a method for improving fertility and reproductive outcomes in females using an androgen and a gonadotropin. The androgen can be DHEA, testosterone, DHEA sulfate, androstenedione, or any other androgen or combination thereof. The gonadotropin can be follicle stimulating hormone (FSH), luteinizing hormone, human menopausal gonadotropin, or any other gonadotropin, or a combination thereof. The method includes administering the androgen for at least six weeks and the gonadotropin for a period longer than two weeks to improve the female's oocyte count and stimulate ovulation. The method also includes monitoring the female's follicle count and repeating the gonadotropin and androgen administration if the follicle count increases during ovulation induction. The androgen can be DHEA and the gonadotropin can be FSH. The combination treatment can be repeated once or multiple times until a desired condition is achieved.

Problems solved by technology

Females with diminished ovarian function (DOF) have decreased egg production and the eggs that are produced usually are of a poor quality.
Further, females with diminished ovarian function often encounter difficulty becoming pregnant with or without IVF, experience long time periods to conception and / or have an increased possibility of miscarriage and / or an increased possibility of having high number / percentages of aneuploid embryos.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Androgen and gonadotropin treatment in females
  • Androgen and gonadotropin treatment in females
  • Androgen and gonadotropin treatment in females

Examples

Experimental program
Comparison scheme
Effect test

example 1

Improved Ovulation after DHEA Treatment

[0050]Example 1 shows the effects of androgen treatment in combination with conventional IVF treatment. These effects are significantly increased in the treatment of the present invention, as shown in Example 2.

[0051]In the example study, a 43 year old woman, Patient A, undergoing IVF with banking of multiple cryopreserved embryos for future aneuploidy screen and transfer, is administered an androgen, namely DHEA. In ten months, she undergoes eight treatment stimulation cycles while continuously improving her ovarian response, resulting in oocyte and embryo yields far beyond those previously seen in a woman her age. Patient A's history is unremarkable except for two previous malarial infections. She is allergic to sulfa medications and has a history of environmental allergies. Her surgical history includes umbilical hernia repair at age one and cholecystectomy at age 21. She had used oral contraceptives for over 10 years. She has no history of ...

example 2

Repeated Ovarian Stimulation Cycles in Conjunction with Androgen Treatment

[0063]Overview of Example 2

[0064]Androgens are understood to improve follicle maturation and ovarian reserve. It is reported that at least one function of androgens at early follicle stages is increasing the sensitivity of granulosa cells to follicle stimulating hormone (FSH). A study investigated the results of repeated ovarian stimulation cycles in women undergoing androgen treatment. The study found that repeated ovarian stimulation cycles spaced less than 120 days apart resulted in higher oocyte yields in later cycles than repeated ovarian stimulation cycles spaced 120 days apart or more than 120 days apart.

[0065]Details of Example 2

[0066]Supported by animal and human data, androgens are now recognized as beneficial to follicle maturation. (Gleicher, et al., The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?, Reproductive Biology and Endocrinology,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
time periodaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and / or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation.

Description

[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 13 / 043,266, filed on Mar. 8, 2011, which is a continuation-in-part of application Ser. No. 12 / 123,877, filed on May 20, 2008, now U.S. Pat. No. 8,067,400 B2, and Ser. No. 12 / 575,426, filed on Oct. 7, 2009, now U.S. Pat. No. 8,501,718 B2, and Ser. No. 12 / 610,215, filed on Oct. 30, 2009, now U.S. Pat. No. 8,501,719 B2, which are incorporated by reference herein in their entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to the field of reproductive technology.[0004]2. Description of the Related Art[0005]The related art of assisted reproductive technology revolutionized the treatment of infertility. The most common assisted reproductive technology is in vitro fertilization (IVF), in which a woman's eggs are harvested and fertilized with a man's sperm in a laboratory. Embryos grown from the fertilized eggs are then chosen to be transferred into the fem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/24A61K31/5685
CPCA61K31/5685A61K38/24A61K31/568A61K2300/00
Inventor GLEICHER, NORBERTBARAD, DAVID H.HARBEN, DWYN V.
Owner GLEICHER NORBERT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com